Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soyeong Yoon

Showing results (11-20 of 11) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 11 results.
Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
Pageof 2

Showing results (11-20 of 11) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 11 results.
Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
Pageof 2